What is the price of Nirmatrelvir/Ritonavir combination?

Nirmatrelvir/Ritonavir, sold under the trade name Paxlovid, is a co-packaged drug used to treat COVID-19, developed by Pfizer. It contains the antiviral drugs Nirmatrelvir/Ritonavir, both of which are protease inhibitors. Nematrelvir inhibits the main protease of the new coronavirus, while ritonavir inhibits the HIV-1 protease and is also a strong CYP3A inhibitor.

In December 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization to the nematvir/ritonavir tablet combination for the treatment of COVID-19. In May 2023, it received full FDA approval for high-risk adults, while children aged 12-18 years are still covered by the emergency use authorization. Side effects of nematvir/ritonavir combination include changes in taste (dysgeusia), diarrhea, high blood pressure (hypertension), and muscle pain (myalgia).

NematrevirThe combination of nematvir/ritonavir tablets has been launched in China. Due to its short time on the market, it has not been included in the medical insurance. The domestic price has not yet been determined. The original drug of nematvir/ritonavir tablet combination marketed overseas, the specification is nematvir 150mg + ritonavir 100mg)*30 tablets per box, the price may be around 2,000 yuan (the price may fluctuate due to the exchange rate), India The price of each box of the generic Nematvir/Ritonavir tablet combination produced by the pharmaceutical factory may be around RMB 1,000 (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.